Antengene Corporation Ltd
HKEX:6996

Watchlist Manager
Antengene Corporation Ltd Logo
Antengene Corporation Ltd
HKEX:6996
Watchlist
Price: 3.84 HKD 4.07% Market Closed
Market Cap: 2.6B HKD

Antengene Corporation Ltd
Other Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Antengene Corporation Ltd
Other Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Antengene Corporation Ltd
HKEX:6996
Other Operating Expenses
ÂĄ23.4m
CAGR 3-Years
N/A
CAGR 5-Years
51%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Other Operating Expenses
-ÂĄ64.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Other Operating Expenses
ÂĄ27.6m
CAGR 3-Years
80%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Other Operating Expenses
ÂĄ438.9m
CAGR 3-Years
24%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Other Operating Expenses
-ÂĄ60.6m
CAGR 3-Years
-74%
CAGR 5-Years
43%
CAGR 10-Years
N/A
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Other Operating Expenses
ÂĄ17.6m
CAGR 3-Years
29%
CAGR 5-Years
-1%
CAGR 10-Years
N/A

Antengene Corporation Ltd
Glance View

Market Cap
2.6B HKD
Industry
Pharmaceuticals

Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.

Intrinsic Value
1.79 HKD
Overvaluation 53%
Intrinsic Value
Price

See Also

What is Antengene Corporation Ltd's Other Operating Expenses?
Other Operating Expenses
23.4m CNY

Based on the financial report for Dec 31, 2023, Antengene Corporation Ltd's Other Operating Expenses amounts to 23.4m CNY.

What is Antengene Corporation Ltd's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 5Y
51%

Back to Top